• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Imaging techniques as predictive and prognostic biomarkers in renal cell carcinoma.影像学技术作为肾细胞癌的预测和预后生物标志物。
Ther Adv Med Oncol. 2013 Mar;5(2):119-31. doi: 10.1177/1758834012463624.
2
Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma.晚期肾细胞癌免疫治疗的预后和预测生物标志物。
Nat Rev Urol. 2023 Mar;20(3):133-157. doi: 10.1038/s41585-022-00676-0. Epub 2022 Nov 21.
3
Diagnostic and prognostic molecular markers in renal cell carcinoma.肾细胞癌的诊断和预后分子标志物
J Urol. 2008 Jun;179(6):2096-102. doi: 10.1016/j.juro.2008.01.083. Epub 2008 Apr 18.
4
Predictive markers in advanced renal cell carcinoma.晚期肾细胞癌的预测标志物。
Semin Oncol. 2013 Aug;40(4):459-64. doi: 10.1053/j.seminoncol.2013.05.001.
5
Biomarkers of renal cell carcinoma.肾细胞癌的生物标志物
Urol Oncol. 2014 Apr;32(3):243-51. doi: 10.1016/j.urolonc.2013.07.011. Epub 2013 Nov 13.
6
Prognostic factors of renal cell carcinoma.肾细胞癌的预后因素。
Rozhl Chir. 2022 Fall;101(10):469-477. doi: 10.33699/PIS.2022.101.10.469-477.
7
Identification and validation of novel prognostic markers in Renal Cell Carcinoma.肾细胞癌中新型预后标志物的鉴定与验证
Dan Med J. 2017 Oct;64(10).
8
Prognostic and predictive biomarkers in renal cell carcinoma.肾细胞癌的预后和预测生物标志物。
Target Oncol. 2010 Jun;5(2):85-94. doi: 10.1007/s11523-010-0143-8. Epub 2010 Jun 28.
9
Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma.新兴免疫疗法在晚期透明细胞肾细胞癌中的应用。
Cells. 2023 Dec 22;13(1):34. doi: 10.3390/cells13010034.
10
Role of imaging biomarkers for prognostic prediction in patients with pancreatic ductal adenocarcinoma.影像生物标志物在胰腺导管腺癌患者预后预测中的作用。
Clin Radiol. 2020 Jun;75(6):478.e1-478.e11. doi: 10.1016/j.crad.2019.12.023. Epub 2020 Feb 6.

引用本文的文献

1
The prognostic and predictive value of vascular response parameters measured by dynamic contrast-enhanced-CT, -MRI and -US in patients with metastatic renal cell carcinoma receiving sunitinib.动态对比增强 CT、MRI 和 US 测量的血管反应参数在接受舒尼替尼治疗的转移性肾细胞癌患者中的预后和预测价值。
Eur Radiol. 2018 Jun;28(6):2281-2290. doi: 10.1007/s00330-017-5220-2. Epub 2018 Jan 30.
2
Dynamic contrast-enhanced and diffusion-weighted magnetic resonance imaging noninvasive evaluation of vascular disrupting treatment on rabbit liver tumors.动态对比增强和扩散加权磁共振成像对兔肝肿瘤血管破坏治疗的无创评估
PLoS One. 2013 Dec 23;8(12):e82649. doi: 10.1371/journal.pone.0082649. eCollection 2013.

本文引用的文献

1
Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course.采用 FDG-PET/CT 对晚期肾细胞癌患者进行早期评估，可预测酪氨酸激酶抑制剂治疗的疾病进程。
BMC Cancer. 2012 May 2;12:162. doi: 10.1186/1471-2407-12-162.
2
Optimisation of the tumour response threshold in patients treated with everolimus for metastatic renal cell carcinoma: analysis of response and progression-free survival in the RECORD-1 study.依维莫司治疗转移性肾细胞癌患者的肿瘤反应阈值优化：RECORD-1 研究中的反应和无进展生存分析。
Eur J Cancer. 2012 Jul;48(10):1512-8. doi: 10.1016/j.ejca.2012.01.027. Epub 2012 Feb 16.
3
Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study.功能磁共振成像技术显示舒尼替尼治疗的肾细胞癌患者早期血管变化：一项初步研究。
Cancer Imaging. 2012 Jan 12;11(1):259-65. doi: 10.1102/1470-7330.2011.0032.
4
Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate.使用 FLT PET/CT 进行药效学研究，评估舒尼替尼治疗肾细胞癌和其他实体恶性肿瘤的效果。
Clin Cancer Res. 2011 Dec 15;17(24):7634-44. doi: 10.1158/1078-0432.CCR-11-1677. Epub 2011 Oct 28.
5
Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.利用治疗前临床表型和初始 CT 改变预测 VEGF 靶向治疗转移性肾细胞癌患者的无进展生存期：初步分析。
Urol Oncol. 2013 Oct;31(7):1283-91. doi: 10.1016/j.urolonc.2011.08.010. Epub 2011 Sep 29.
6
Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy.分子靶向治疗早期随访中转移性肾细胞癌病变的大小和密度变化过程。
Urol Oncol. 2012 Sep;30(5):695-703. doi: 10.1016/j.urolonc.2010.10.011. Epub 2011 Aug 24.
7
Dynamic microbubble contrast-enhanced US to measure tumor response to targeted therapy: a proposed clinical protocol with results from renal cell carcinoma patients receiving antiangiogenic therapy.动态微泡超声造影评估靶向治疗的肿瘤反应：一项临床方案研究，入组接受抗血管生成治疗的肾癌患者的结果。
Radiology. 2011 Aug;260(2):581-90. doi: 10.1148/radiol.11101893. Epub 2011 May 9.
8
Tumor size is a potential predictor of response to tyrosine kinase inhibitors in renal cell cancer.肿瘤大小是预测肾细胞癌对酪氨酸激酶抑制剂反应的一个潜在指标。
Urology. 2011 Apr;77(4):831-5. doi: 10.1016/j.urology.2010.12.008. Epub 2011 Feb 12.
9
The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer.舒尼替尼用于计划行肾切除术的转移性透明细胞肾细胞癌患者的安全性和疗效。
Ann Oncol. 2011 May;22(5):1041-1047. doi: 10.1093/annonc/mdq564. Epub 2011 Jan 17.
10
Evaluation of response to multikinase inhibitor in metastatic renal cell carcinoma by FDG PET/contrast-enhanced CT.采用 FDG PET/对比增强 CT 评估转移性肾细胞癌对多激酶抑制剂的反应。
Clin Nucl Med. 2010 Dec;35(12):918-23. doi: 10.1097/RLU.0b013e3181f9ddd9.

影像学技术作为肾细胞癌的预测和预后生物标志物。

Imaging techniques as predictive and prognostic biomarkers in renal cell carcinoma.

机构信息

Mount Vernon Cancer Centre - Medical Oncology, Rickmansworth Road, Northwood, Middlesex HA6 2RN, UK.

出版信息

Ther Adv Med Oncol. 2013 Mar;5(2):119-31. doi: 10.1177/1758834012463624.

DOI:10.1177/1758834012463624
PMID:23450112
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3556873/
Abstract

A number of imaging modalities are showing promise as predictive and prognostic biomarkers in advanced renal cell carcinoma. This review discusses progress to date in this exciting area and identifies areas of future promise.

摘要

多种影像学方法在晚期肾细胞癌的预测和预后生物标志物方面显示出前景。本文讨论了这一令人兴奋领域的最新进展，并确定了未来有希望的领域。